Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk

Dow Jones

Mar 24, 2025

0908 GMT - Novo Nordisk shares will likely remain under pressure in the near term following disappointing CagriSema weight-loss drug data, Berenberg analysts write. The company still offers superior sales growth until the end of the decade, but its CagriSema woes have brought the patent expiry of semaglutide--the main ingredient in Ozempic and Wegovy--into full focus. "Novo's obesity pipeline remains more limited than Eli Lilly's and the competitive threat of an oral GLP-1 with equivalence to Wegovy weighs heavy." The bank says consensus Wegovy expectations are too high, and notes a growing preference for Lilly's Zepbound over Novo's Wegovy. Berenberg lowers its price target to 610 Danish kroner from 725 kroner and reiterates its hold rating. Shares fall 0.9% to 524 kroner. (dominic.chopping@wsj.com)

(END) Dow Jones Newswires

March 24, 2025 05:08 ET (09:08 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2521797248"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2521797248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2521797248?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-24 17:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2521797248","market":"us","top_or_hot":-1,"title":"Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0908 GMT - Novo Nordisk shares will likely remain under pressure in the near term following disappointing CagriSema weight-loss drug data, Berenberg analysts write. The company still offers superior sales growth until the end of the decade, but its CagriSema woes have brought the patent expiry of semaglutide--the main ingredient in Ozempic and Wegovy--into full focus. \"Novo's obesity pipeline remains more limited than Eli Lilly's and the competitive threat of an oral GLP-1 with equivalence to Wegovy weighs heavy.\" The bank says consensus Wegovy expectations are too high, and notes a growing preference for Lilly's Zepbound over Novo's Wegovy. Berenberg lowers its price target to 610 Danish kroner from 725 kroner and reiterates its hold rating. Shares fall 0.9% to 524 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 05:08 ET (09:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk Shares Could Remain Under Pressure for Now -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-03-24 17:08</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0908 GMT - Novo Nordisk shares will likely remain under pressure in the near term following disappointing CagriSema weight-loss drug data, Berenberg analysts write. The company still offers superior sales growth until the end of the decade, but its CagriSema woes have brought the patent expiry of semaglutide--the main ingredient in Ozempic and Wegovy--into full focus. \"Novo's obesity pipeline remains more limited than Eli Lilly's and the competitive threat of an oral GLP-1 with equivalence to Wegovy weighs heavy.\" The bank says consensus Wegovy expectations are too high, and notes a growing preference for Lilly's Zepbound over Novo's Wegovy. Berenberg lowers its price target to 610 Danish kroner from 725 kroner and reiterates its hold rating. Shares fall 0.9% to 524 kroner. (dominic.chopping@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 24, 2025 05:08 ET (09:08 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4532","symbol_name":"文艺复兴科技持仓","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2521797248","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2521797248","pubTimestamp":1742807280,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0908 GMT - Novo Nordisk shares will likely remain under pressure in the near term following disappointing CagriSema weight-loss drug data, Berenberg analysts write. The company still offers superior sales growth until the end of the decade, but its CagriSema woes have brought the patent expiry of semaglutide--the main ingredient in Ozempic and Wegovy--into full focus. \"Novo's obesity pipeline remains more limited than Eli Lilly's and the competitive threat of an oral GLP-1 with equivalence to Wegovy weighs heavy.\" The bank says consensus Wegovy expectations are too high, and notes a growing preference for Lilly's Zepbound over Novo's Wegovy. Berenberg lowers its price target to 610 Danish kroner from 725 kroner and reiterates its hold rating. Shares fall 0.9% to 524 kroner. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","NVO":"诺和诺德","BK4585":"ETF&股票定投概念","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4599":"减肥药"},"translate_title":"诺和诺德股价目前可能仍面临压力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"0908 GMT - Novo Nordisk shares will likely remain under pressure in the near term following disappointing CagriSema weight-loss drug data, Berenberg analysts write. The company still offers superior sales growth until the end of the decade, but its CagriSema woes have brought the patent expiry of semaglutide--the main ingredient in Ozempic and Wegovy--into full focus. \"Novo's obesity pipeline remains more limited than Eli Lilly's and the competitive threat of an oral GLP-1 with equivalence to Wegovy weighs heavy.\" The bank says consensus Wegovy expectations are too high, and notes a growing preference for Lilly's Zepbound over Novo's Wegovy. Berenberg lowers its price target to 610 Danish kroner from 725 kroner and reiterates its hold rating. Shares fall 0.9% to 524 kroner. (dominic.chopping@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2025 05:08 ET (09:08 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}